A citation-based method for searching scientific literature

Toshie Manabe, Dan Kambayashi, Hiroyasu Akatsu, Koichiro Kudo. BMC Infect Dis 2021
Times Cited: 45







List of co-cited articles
375 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Soheil Hassanipour, Morteza Arab-Zozani, Bahman Amani, Forough Heidarzad, Mohammad Fathalipour, Rudolph Martinez-de-Hoyo. Sci Rep 2021
80
46

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Qingxian Cai, Minghui Yang, Dongjing Liu, Jun Chen, Dan Shu, Junxia Xia, Xuejiao Liao, Yuanbo Gu, Qiue Cai, Yang Yang,[...]. Engineering (Beijing) 2020
670
40

Remdesivir for the Treatment of Covid-19 - Final Report.
John H Beigel, Kay M Tomashek, Lori E Dodd, Aneesh K Mehta, Barry S Zingman, Andre C Kalil, Elizabeth Hohmann, Helen Y Chu, Annie Luetkemeyer, Susan Kline,[...]. N Engl J Med 2020
37

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Andrey A Ivashchenko, Kirill A Dmitriev, Natalia V Vostokova, Valeria N Azarova, Andrew A Blinow, Alina N Egorova, Ivan G Gordeev, Alexey P Ilin, Ruben N Karapetian, Dmitry V Kravchenko,[...]. Clin Infect Dis 2021
128
35

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Zarir F Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F Caracta, Monika Tandon. Int J Infect Dis 2021
107
35

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Yohei Doi, Masaya Hibino, Ryota Hase, Michiko Yamamoto, Yu Kasamatsu, Masahiro Hirose, Yoshikazu Mutoh, Yoshito Homma, Masaki Terada, Taku Ogawa,[...]. Antimicrob Agents Chemother 2020
98
28

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang, Ruiyuan Cao, Leike Zhang, Xinglou Yang, Jia Liu, Mingyue Xu, Zhengli Shi, Zhihong Hu, Wu Zhong, Gengfu Xiao. Cell Res 2020
28

Role of favipiravir in the treatment of COVID-19.
Shashank Joshi, Jalil Parkar, Abdul Ansari, Agam Vora, Deepak Talwar, Mangesh Tiwaskar, Saiprasad Patil, Hanmant Barkate. Int J Infect Dis 2021
111
28

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Hongchao Pan, Richard Peto, Ana-Maria Henao-Restrepo, Marie-Pierre Preziosi, Vasee Sathiyamoorthy, Quarraisha Abdool Karim, Marissa M Alejandria, César Hernández García, Marie-Paule Kieny, Reza Malekzadeh,[...]. N Engl J Med 2021
26

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Yousuke Furuta, Takashi Komeno, Takaaki Nakamura. Proc Jpn Acad Ser B Phys Biol Sci 2017
487
26

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao, Yeming Wang, Danning Wen, Wen Liu, Jingli Wang, Guohui Fan, Lianguo Ruan, Bin Song, Yanping Cai, Ming Wei,[...]. N Engl J Med 2020
24

Effectiveness of favipiravir in COVID-19: a live systematic review.
Batu Özlüşen, Şima Kozan, Rüştü Emre Akcan, Mekselina Kalender, Doğukan Yaprak, İbrahim Batuhan Peltek, Şiran Keske, Mehmet Gönen, Önder Ergönül. Eur J Clin Microbiol Infect Dis 2021
13
76

Favipiravir: A new and emerging antiviral option in COVID-19.
Umang Agrawal, Reyma Raju, Zarir F Udwadia. Med J Armed Forces India 2020
139
22

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu,[...]. Eur J Pharm Sci 2021
90
20

A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
Victoria Pilkington, Toby Pepperrell, Andrew Hill. J Virus Erad 2020
83
20

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang, Dingyu Zhang, Guanhua Du, Ronghui Du, Jianping Zhao, Yang Jin, Shouzhi Fu, Ling Gao, Zhenshun Cheng, Qiaofa Lu,[...]. Lancet 2020
17

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Hany M Dabbous, Sherief Abd-Elsalam, Manal H El-Sayed, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Samir Abd El Ghafar, Shaimaa Soliman, Mohamed Elbahnasawy, Rehab Badawi, Mohamed Awad Tageldin. Arch Virol 2021
51
17

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial.
Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, Yuji Hirai, Sho Fujiwara, Yuko Komase, Takeshi Saraya,[...]. Infect Dis Ther 2021
23
34

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Christoph D Spinner, Robert L Gottlieb, Gerard J Criner, José Ramón Arribas López, Anna Maria Cattelan, Alex Soriano Viladomiu, Onyema Ogbuagu, Prashant Malhotra, Kathleen M Mullane, Antonella Castagna,[...]. JAMA 2020
625
15

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, Grégory Moureau, Franck Touret, Paul-Rémi Petit, Géraldine Piorkowski, Karine Barthélémy, Caroline Laprie, Bruno Coutard,[...]. Nat Commun 2021
61
15

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Faryal Khamis, Hanan Al Naabi, Adil Al Lawati, Zaiyana Ambusaidi, Mariam Al Sharji, Umkulthum Al Barwani, Nenad Pandak, Zakariya Al Balushi, Maher Al Bahrani, Issa Al Salmi,[...]. Int J Infect Dis 2021
41
17

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Masoud Solaymani-Dodaran, Mostafa Ghanei, Mehdi Bagheri, Ali Qazvini, Ensieh Vahedi, Seyed Hassan Saadat, Seyed Amin Setarehdan, Akram Ansarifar, Hossein Biganeh, Arash Mohazzab,[...]. Int Immunopharmacol 2021
26
26

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D Goldman, David C B Lye, David S Hui, Kristen M Marks, Raffaele Bruno, Rocio Montejano, Christoph D Spinner, Massimo Galli, Mi-Young Ahn, Ronald G Nahass,[...]. N Engl J Med 2020
761
15

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Yousuke Furuta, Brian B Gowen, Kazumi Takahashi, Kimiyasu Shiraki, Donald F Smee, Dale L Barnard. Antiviral Res 2013
565
15

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Virginia Delos Reyes, Alejandro Martín-Quirós, Yoseph Caraco, Angela Williams-Diaz, Michelle L Brown,[...]. N Engl J Med 2022
341
15


Dexamethasone in Hospitalized Patients with Covid-19.
Peter Horby, Wei Shen Lim, Jonathan R Emberson, Marion Mafham, Jennifer L Bell, Louise Linsell, Natalie Staplin, Christopher Brightling, Andrew Ustianowski, Einas Elmahi,[...]. N Engl J Med 2021
13

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial.
Chang Chen, Yi Zhang, Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu,[...]. Front Pharmacol 2021
21
28

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
James M Sanders, Marguerite L Monogue, Tomasz Z Jodlowski, James B Cutrell. JAMA 2020
13

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, Kay M Tomashek, Cameron R Wolfe, Varduhi Ghazaryan, Vincent C Marconi, Guillermo M Ruiz-Palacios, Lanny Hsieh, Susan Kline,[...]. N Engl J Med 2021
785
13

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, Cédric Laouénan, Vincent Madelain, Anne-Marie Taburet, Sylvain Baize, Daouda Sissoko, Boris Pastorino, Anne Rodallec,[...]. PLoS Negl Trop Dis 2017
96
11

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Hany M Dabbous, Manal H El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F S Ebeid, Ahmed F Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M Hassany, Ahmed R Riad,[...]. Sci Rep 2021
27
18


Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Hong Zhao, Qi Zhu, Chi Zhang, Jiawen Li, Ming Wei, Yuhong Qin, Guilin Chen, Ke Wang, Junhua Yu, Zhao Wu,[...]. Biomed Pharmacother 2021
42
11

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Hong Zhao, Chi Zhang, Qi Zhu, Xianxiang Chen, Guilin Chen, Wenjin Sun, Zuohan Xiao, Weijun Du, Jing Yao, Guojun Li,[...]. Int Immunopharmacol 2021
14
35

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Dhan Bahadur Shrestha, Pravash Budhathoki, Sitaram Khadka, Prajwol Bikram Shah, Nisheem Pokharel, Prama Rashmi. Virol J 2020
44
11


Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Jonathan Grein, Norio Ohmagari, Daniel Shin, George Diaz, Erika Asperges, Antonella Castagna, Torsten Feldt, Gary Green, Margaret L Green, François-Xavier Lescure,[...]. N Engl J Med 2020
11

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Leon Caly, Julian D Druce, Mike G Catton, David A Jans, Kylie M Wagstaff. Antiviral Res 2020
969
8


Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
Ping-Jen Chen, Chien-Ming Chao, Chih-Cheng Lai. J Infect 2021
14
28

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
Vincent Madelain, Thi Huyen Tram Nguyen, Anaelle Olivo, Xavier de Lamballerie, Jérémie Guedj, Anne-Marie Taburet, France Mentré. Clin Pharmacokinet 2016
84
8

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida. Clin Transl Sci 2020
40
10


SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche,[...]. Cell 2020
8

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Suzanne J F Kaptein, Sofie Jacobs, Lana Langendries, Laura Seldeslachts, Sebastiaan Ter Horst, Laurens Liesenborghs, Bart Hens, Valentijn Vergote, Elisabeth Heylen, Karine Barthelemy,[...]. Proc Natl Acad Sci U S A 2020
140
8

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Martin J Vincent, Eric Bergeron, Suzanne Benjannet, Bobbie R Erickson, Pierre E Rollin, Thomas G Ksiazek, Nabil G Seidah, Stuart T Nichol. Virol J 2005
8

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
Marzieh Nojomi, Zeynab Yassin, Hossein Keyvani, Mahin Jamshidi Makiani, Maryam Roham, Azadeh Laali, Nasir Dehghan, Mehrnaz Navaei, Mitra Ranjbar. BMC Infect Dis 2020
55
8

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu,[...]. Lancet 2020
8

In vitro and in vivo activities of anti-influenza virus compound T-705.
Y Furuta, K Takahashi, Y Fukuda, M Kuno, T Kamiyama, K Kozaki, N Nomura, H Egawa, S Minami, Y Watanabe,[...]. Antimicrob Agents Chemother 2002
318
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.